Selecta Biosciences, Inc., a Watertown, MA-based biopharmaceutical company developing synthetic nanoparticle vaccines and immunotherapies, has been awarded a $3m grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH). The grant is aimed at advancing the development of an enhanced therapeutic nicotine vaccine for the treatment of smoking cessation and relapse prevention from preclinical through early clinical evaluation.
The award is provided by NIH under the BRDG-SPAN program (Biomedical Research and Development and Growth To Spur the Acceleration of New Technologies Pilot Program), which is designed to bridge the gap between R&D and commercialization for promising new medical technologies.
Founded in 2008 by Professor Robert Langer (MIT), Professors Omid Farokhzad and Ulrich von Andrian (Harvard Medical School), Selecta develops synthetic nanoparticle vaccines and immunotherapies using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology.
Selecta is backed by venture investors including, Polaris Venture Partners, Flagship Ventures, NanoDimension, OrbiMed Advisors and Leukon Investments. Earlier this year, the company raised $15m in Series C financing.
FinSMEs
17/08/2010